St Paul, Minnesota, September 15, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the Inflammation Research Association (IRA) International Conference, September 21-24, Chantilly, VA. Capabilities featured will be pre-clinical efficacy disease models and research products for drug discovery and research.
MD Biosciences will be hosting a lunch and learn session titled “Discovery of novel therapies for asthma requires suitable and relevant disease models”. Conference attendees are invited to register for this free session upon arrival of the conference. This session will focus on the OVA-induced Asthma model and airway hyperresponsiveness (AHR) as well as the OVA-IgE specific ELISA for measuring OVA specific IgE levels in murine serum samples.
MD Biosciences services that will be featured throughout the conference include the Collagen-Induced Arthritis (CIA), Collagen Antibody-induced Arthritis (CAIA), Adjuvant Induced arthritis (AIA), Monoarthritic Pain, OVA-induced Asthma along with general inflammation assays. Products include collagen related reagents and assays, ArthritoMab™ antibody cocktail, OVA-IgE ELISA, Aggrecan antibodies and T-cell antibodies.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.